The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), was awarded a $1,568,220 Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING HETEROGENEITY IN NF2-MUTANT TUMORS". The award, which commenced on September 15, 2024 and is scheduled for completion by September 14, 2027, will support MGH's cutting-edge biomedical research in areas such as cancer, neurological disorders, and other disease states that are relevant to military and veteran populations. As a renowned academic medical center, MGH has a strong track record of securing federal grant funding from the National Institutes of Health and other agencies to advance its extensive research program, which includes clinical trials, laboratory studies, and the development of new treatments and diagnostics.
Generated 2/25/25, 5:10 AM